JP2016514672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514672A5 JP2016514672A5 JP2016501829A JP2016501829A JP2016514672A5 JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5 JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016501829 A JP2016501829 A JP 2016501829A JP 2016514672 A5 JP2016514672 A5 JP 2016514672A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- antigen
- nucleic acid
- subject
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 7
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000223960 Plasmodium falciparum Species 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 claims 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361788942P | 2013-03-15 | 2013-03-15 | |
| US61/788,942 | 2013-03-15 | ||
| PCT/US2014/025348 WO2014151279A1 (en) | 2013-03-15 | 2014-03-13 | Vaccines having an antigen and interleukin-23 as an adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514672A JP2016514672A (ja) | 2016-05-23 |
| JP2016514672A5 true JP2016514672A5 (cg-RX-API-DMAC7.html) | 2017-03-30 |
Family
ID=51580923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501829A Pending JP2016514672A (ja) | 2013-03-15 | 2014-03-13 | 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9669091B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968500A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016514672A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150128900A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105209063A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014235120B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2898237A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014151279A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2733377T3 (es) * | 2013-10-07 | 2019-11-28 | Univ Pennsylvania | Vacunas con interleucina-33 como adyuvante |
| EP3747459A4 (en) * | 2018-02-02 | 2021-12-01 | SL Vaxigen, Inc. | NEW IMMUNOADJUVANT VACCINE |
| CN108383913A (zh) * | 2018-02-12 | 2018-08-10 | 四川大学 | 重组猪il-23增强pcv2疫苗免疫佐剂的制备及应用 |
| KR102285977B1 (ko) * | 2019-03-15 | 2021-08-05 | 대한민국 | 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물 |
| EP4069284A1 (en) | 2019-12-03 | 2022-10-12 | Neuvogen, Inc. | Tumor cell vaccines |
| TW202146435A (zh) * | 2020-03-04 | 2021-12-16 | 美商昂科賽醫藥公司 | 含有病原性抗原及免疫刺激物之組合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113817A (en) * | 1994-06-30 | 2001-03-19 | Merck & Co Inc | Polynucleotide vaccne for papillomavirus |
| WO2003084467A2 (en) * | 2002-04-01 | 2003-10-16 | Euro-Celtique S.A. | Epitope constructs comprising antigen presenting cell targeting mechanisms |
| GB0329146D0 (en) * | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
| BRPI0615400A2 (pt) * | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| EP1988919A4 (en) * | 2006-02-02 | 2009-06-10 | Globeimmune Inc | VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE |
| US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
| JP5972871B2 (ja) * | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| US9226958B2 (en) * | 2010-10-01 | 2016-01-05 | University Of Georgia Research Foundation, Inc. | Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| US8802076B2 (en) * | 2010-10-04 | 2014-08-12 | Duke University | Compositions and methods for modulating an immune response |
| AU2012352457B2 (en) * | 2011-12-12 | 2016-04-21 | The Trustees Of The University Of Pennsylvania | Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
| CN102876684B (zh) * | 2012-09-17 | 2014-10-08 | 青岛康立泰药业有限公司 | 人白细胞介素-12的编码基因、真核宿主细胞和表达方法 |
-
2014
- 2014-03-13 WO PCT/US2014/025348 patent/WO2014151279A1/en not_active Ceased
- 2014-03-13 JP JP2016501829A patent/JP2016514672A/ja active Pending
- 2014-03-13 AU AU2014235120A patent/AU2014235120B2/en not_active Ceased
- 2014-03-13 CN CN201480013830.6A patent/CN105209063A/zh active Pending
- 2014-03-13 US US14/775,087 patent/US9669091B2/en active Active
- 2014-03-13 KR KR1020157028132A patent/KR20150128900A/ko not_active Ceased
- 2014-03-13 EP EP14767446.9A patent/EP2968500A4/en not_active Withdrawn
- 2014-03-13 CA CA2898237A patent/CA2898237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520530A5 (cg-RX-API-DMAC7.html) | ||
| JP2016514672A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526580A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516723A5 (cg-RX-API-DMAC7.html) | ||
| FI4023249T3 (fi) | Nukleiinihapporokotteita | |
| JP2016539946A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506416A5 (cg-RX-API-DMAC7.html) | ||
| MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| WO2016207853A3 (en) | Antigenically matched influenza vaccines | |
| JP2015501840A5 (cg-RX-API-DMAC7.html) | ||
| Rezaei et al. | Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials | |
| MX2020011804A (es) | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. | |
| MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| Vemula et al. | Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time | |
| WO2008060385A3 (en) | Li-key enhanced vaccine potency | |
| Garg et al. | Development of novel carrier (s) mediated tuberculosis vaccine: more than a tour de force | |
| JP2010506926A5 (cg-RX-API-DMAC7.html) | ||
| JP2014139185A5 (cg-RX-API-DMAC7.html) | ||
| JP2019505567A5 (cg-RX-API-DMAC7.html) | ||
| JP2018501258A5 (cg-RX-API-DMAC7.html) | ||
| AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
| WO2011038473A8 (pt) | Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos | |
| EA033242B1 (ru) | Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением | |
| PH12014502085B1 (en) | Modified marek`s disease virus, and vaccines made therefrom |